What happened
Nexomic, a Dublin-based biomarker intelligence company, unveiled an AI-driven precision oncology solution. It integrates multi-omic data, using "AI Precision oncology biomarkers" and "AI Systems-biology-driven omics" to generate comprehensive molecular signatures from genomic, transcriptomic, epigenomic, proteomic, metabolic, and immune signals. This approach aims for accurate patient stratification, optimised therapy selection, and improved treatment response prediction, reducing clinical trial failures and accelerating drug development, according to Nexomic. Its commitment to explainability ensures biologically interpretable, clinically meaningful biomarker outputs.
Why it matters
This development shifts how drug developers identify patient subgroups and how oncologists select therapies. For clinical trial procurement teams, the platform's ability to predict therapy response and reduce trial failures offers a mechanism to cut development timelines and costs. Security architects and platform engineers must prioritise integrating explainable AI outputs, as Nexomic's commitment to interpretable biomarkers is crucial for fostering trust and adoption in clinical decision-making. This advances personalised medicine by moving beyond single biomarkers to multi-dimensional intelligence.
